TY - JOUR
T1 - Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy
T2 - a retrospective cohort study
AU - Jensen-Fangel, S
AU - Kirk, O
AU - Larsen, L
AU - Blaxhult, A
AU - Gerstoft, J
AU - Pedersen, C
AU - Black, F T
AU - Lundgren, J D
AU - Obel, N
PY - 1999
Y1 - 1999
N2 - Protease inhibitors are important components in anti-retroviral regimens. In this retrospective study 29 HIV-infected patients treated with a regimen of zidovudine, lamivudine and saquinavir hard gel in 1 centre in Denmark were compared with 58 patients treated with zidovudine, lamivudine and ritonavir or indinavir followed at 5 other centres in Scandinavia. All patients were naive to anti-retroviral therapy prior to institution of the actual anti-retroviral regimen and were followed for a median of 1.3 and 1.4 y respectively. The 2 groups did not differ significantly with respect to age, gender, route of infection, ethnic background, viral load, CD4 count, AIDS at baseline or frequency of clinical controls. Six and 12 months after initiating anti-retroviral therapy, 31% and 34% of the patients on the saquinavir regimen obtained HIV-RNA < or = 500 compared with 76% and 73% in the control group (p < 0.001). In contrast to viral load, the increase in CD4 count did not differ significantly between the 2 groups. In conclusion, we found that with respect to suppression of viral load a regimen of saquinavir, zidovudine and lamivudine seemed to be inferior to a regimen of zidovudine, lamivudine and ritonavir or indinavir.
AB - Protease inhibitors are important components in anti-retroviral regimens. In this retrospective study 29 HIV-infected patients treated with a regimen of zidovudine, lamivudine and saquinavir hard gel in 1 centre in Denmark were compared with 58 patients treated with zidovudine, lamivudine and ritonavir or indinavir followed at 5 other centres in Scandinavia. All patients were naive to anti-retroviral therapy prior to institution of the actual anti-retroviral regimen and were followed for a median of 1.3 and 1.4 y respectively. The 2 groups did not differ significantly with respect to age, gender, route of infection, ethnic background, viral load, CD4 count, AIDS at baseline or frequency of clinical controls. Six and 12 months after initiating anti-retroviral therapy, 31% and 34% of the patients on the saquinavir regimen obtained HIV-RNA < or = 500 compared with 76% and 73% in the control group (p < 0.001). In contrast to viral load, the increase in CD4 count did not differ significantly between the 2 groups. In conclusion, we found that with respect to suppression of viral load a regimen of saquinavir, zidovudine and lamivudine seemed to be inferior to a regimen of zidovudine, lamivudine and ritonavir or indinavir.
KW - Adult
KW - Anti-HIV Agents/therapeutic use
KW - CD4 Lymphocyte Count/drug effects
KW - Controlled Clinical Trials as Topic
KW - Denmark
KW - Drug Therapy, Combination
KW - Female
KW - HIV Infections/drug therapy
KW - HIV Protease Inhibitors/pharmacokinetics
KW - Humans
KW - Indinavir/therapeutic use
KW - Lamivudine/therapeutic use
KW - Male
KW - Multicenter Studies as Topic
KW - RNA, Viral/drug effects
KW - Retrospective Studies
KW - Ritonavir/therapeutic use
KW - Saquinavir/pharmacokinetics
KW - Viral Load
KW - Zidovudine/therapeutic use
U2 - 10.1080/00365549950164021
DO - 10.1080/00365549950164021
M3 - Journal article
C2 - 10576129
SN - 0036-5548
VL - 31
SP - 489
EP - 493
JO - Scandinavian Journal of Infectious Diseases
JF - Scandinavian Journal of Infectious Diseases
IS - 5
ER -